Category
Molly Treatment
The psychoactive drug MDMA, commonly known as molly, combined with psychotherapy could revolutionize the treatment of Post Traumatic Stress Disorder (PTSD), which affects approximately 9 million individuals in the United States annually. In 2017, the Food and Drug Administration (FDA) granted breakthrough therapy status to MDMA-assisted psychotherapy. Despite this progress, the compound remains classified as a Schedule 1 drug, alongside marijuana, heroin, and LSD, due to the government’s assertion that these substances have no accepted medical use and a heightened risk of abuse. The protocol employed in this research utilizes pure doses of the substance, along with residential stays and outpatient psychotherapy sessions, rather than the street version. Fortunately, a foundation dedicated to supporting Navy SEALs, among the most highly accomplished individuals globally, emerged as the first military-serving nonprofit organization to generously fund critical research into MDMA-assisted psychotherapy for PTSD. Proponents of the MAPS Multidisciplinary Association for Psychedelic Studies research believe that this approach has the potential to revolutionize the treatment of PTSD, which affects nearly 9 million Americans. The research has received substantial support, with nearly 30 million dollars raised from various donors. The foundation’s commitment to this research was motivated by SEALs who have experienced relief from PTSD through such treatment outside the United States. The drug appears to enhance feelings of trust, facilitate the recollection of traumatic memories, and diminish the fear response. However, patients who do not find relief through conventional methods will have access to treatment with Molly and or MDMA. While many individuals with milder symptoms of PTSD may be adequately treated with long-term psychotherapy, those who require more intensive intervention will benefit from MDMA-assisted therapy.
